Table 1 Performance comparison across sample cohorts
Performance of genetic alterations (Variants and Fusions) | ||||||
|---|---|---|---|---|---|---|
| Â | Â | Â | Cancer prevalence used in calculation | |||
| Â | Â | Â | PPV | NPV | ||
Sample cohort | Sensitivity | Specificity | 24Â % | 40Â % | 24Â % | 40Â % |
All VERA FNA (n = 88) | 43 % (28–59) | 84 % (70–93) | 46 % (29–65) | 64 % (46–79) | 82 % (78–86) | 69 % (62–75) |
AUS/FLUS & FN/SFN only VERA FNA (n = 22) | 33 % (1–91) | 84 % (60–97) | 40 % (9–82) | 58 % (17–90) | 80 % (64–90) | 65 % (45–81) |
Tissue (n = 63) | 59 % (41–76) | 74 % (55–88) | 42 % (27–58) | 61 % (44–75) | 85 % (78–90) | 73 % (63–81) |
Combined VERA FNA and tissue (n = 151) | 50 % (38–62) | 80 % (69–88) | 44 % (32–57) | 63 % (50–73) | 84 % (80–87) | 71 % (65–76) |